Ellagic acid protects the brain against 6-hydroxydopamine induced neuroinflammation in a rat model of parkinson's disease

Basic and Clinical Neuroscience

Volumn 6, Issue 2, 2015, Pages 15-22

  Farbood, Yaghoob ^a   Sarkaki, Alireza ^a   Dolatshahi, Mojtaba ^b   Mansouri, Seyed Mohammad Taqhi ^a   Khodadadi, Ali ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b DEZFUL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Activity; Antioxidants; Ellagic acid; Inflammation; Parkinson's disease; Rat

Indexed keywords

APOMORPHINE; ELLAGIC ACID; INTERLEUKIN 1BETA; OXIDOPAMINE; PRAMIPEXOLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN PROTECTION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MARKER; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; RAT;

EID: 84928386115     PISSN: 2008126X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Block, M. L., & Hong, J. S. (2005). Microglia and inflammationmediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol, 76(2), 77-98. doi: 10.1016/j.pneurobio.2005.06.004
2. Braidy, N., Selvaraju, S., Essa, M. M., Vaishnav, R., Al-Adawi, S., Al-Asmi, A., Guillemin, G. J. et al., (2013). Neuroprotective effects of a variety of pomegranate juice extracts against MPTPinduced cytotoxicity and oxidative stress in human primary neurons. Oxidative Medicine and Cellular Longevity, 4(4): 232-238. doi: 10.1155/2013/685909.
3. Chaturvedi, R. K., Shukla, S., Seth, K., Chauhan, S., Sinha, C., Shukla, Y., & Agrawal, A. K. (2006). Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopaminelesioned rat model of Parkinson's disease. Neurobiol Dis, 22(2), 421-434. doi: 10.1016/j.nbd.2005.12.008
4. Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005). Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol, 58(6), 963-967. doi: 10.1002/ana.20682.
5. Chis, I. C., Ungureanu, M. I., Marton, A., Simedrea, R., Muresan, A., Postescu, I. D., & Decea, N. (2009). Antioxidant effects of a grape seed extract in a rat model of diabetes mellitus. Diabetes & Vascular Disease Research, 6(3), 200-204. doi: 10.1177/1479164109336692
6. Dauer, W., & Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron, 39(6), 889-909.
7. Esposito, E., Rotilio, D., Di Matteo, V., Di Giulio, C., Cacchio, M., & Algeri, S. (2002). A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging, 23(5), 719-735.
8. Fahn, S., & Sulzer, D. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx, 1(1), 139-154. doi: 10.1602/neurorx.1.1.139
9. Ferrari, C. C., Pott Godoy, M. C., Tarelli, R., Chertoff, M., Depino, A. M., & Pitossi, F. J. (2006). Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis, 24(1), 183-193. doi: 10.1016/j.nbd.2006.06.013
10. Hritcu, L., Ciobica, A., & Artenie, V. (2008). Effects of rightunilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson's disease. Central European Journal of Biology, 3(3), 250-257. doi: 10.2478/s11535-008-0023-8
11. Huang, Z., de la Fuente-Fernandez, R., & Stoessl, A. J. (2003). Etiology of Parkinson's disease. Canadian Journal of Neurological Sciences, 30 Suppl 1, S10-18.
12. Hwang, D. S., Kim, H. G., Kwon, H. J., Cho, J. H., Lee, C. H., Lee, J. M., Oh, M. S. et al., (2011). Dangguijakyak-san, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced neurotoxicity. J Ethnopharmacol, 133(2), 934-939. doi: 10.1016/j.jep.2010.11.017
13. Kelly, E., Jenner, P., & Marsden, C. D. (1984). Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat. Exp Brain Res, 55(2), 243-252.
14. Leal, M. C., Casabona, J. C., Puntel, M., & Pitossi, F. J. (2013). Interleukin-1beta and tumor necrosis factor-alpha: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci, 7, 53. doi: 10.3389/fncel.2013.00053
15. Lei, F., Xing, D. M., Xiang, L., Zhao, Y. N., Wang, W., Zhang, L. J., & Du, L. J. (2003). Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. Journal of Chromatography. B: Analytical Technologies in the Biomedical and Life Sciences, 796(1), 189-194.
16. Metz, G. A., Tse, A., Ballermann, M., Smith, L. K., & Fouad, K. (2005). The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis. Eur J Neurosci, 22(3), 735-744. doi: 10.1111/j.1460-9568.2005.04238.x
17. Miguel, G., Dandlen, S., Antunes, D., Neves, A., & Martins, D. (2004). The Effect of Two Methods of Pomegranate (Punica granatum L) Juice Extraction on Quality During Storage at 4°C. Journal of Biomedicine and Biotechnology, 2004(5), 332-337. doi: 10.1155/s1110724304403064
18. Moreira, E. L., Rial, D., Aguiar, A. S., Jr., Figueiredo, C. P., Siqueira, J. M., DalBo, S., Prediger, R. D., et al., (2010). Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm, 117(12), 1337-1351. doi: 10.1007/s00702-010-0464-x
19. Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Halliday, G., et. al. (2010). Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 16(6), 653-661. doi: 10.1038/nm.2165
20. Paxinos, G., & Watson, C. (2006). The rat brain stereotaxic coordinates. Australia: Academic Press.
21. Philippens, I. H., t Hart, B. A., & Torres, G. (2010). The MPTP marmoset model of parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases. Drug Discovery Today, 15(23-24), 985-990. doi: 10.1016/j.drudis.2010.08.009
22. Rizelio, V., Szawka, R. E., Xavier, L. L., Achaval, M., Rigon, P., Saur, L., Ferraz, A. C., et. el. (2010). Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease. Braz J Med Biol Res, 43(1), 85-95.
23. Roof, R. L., Schielke, G. P., Ren, X., & Hall, E. D. (2001). A Comparison of Long-Term Functional Outcome After 2 Middle Cerebral Artery Occlusion Models in Rats. Stroke, 32(11), 2648-2657. doi: 10.1161/hs1101.097397
24. Sarkaki, A., Norooz Zare, F., Farbood, Y., & Pileverian, A. (2013). [Impaired movements in 6-OHDA induced Parkinson's rat model improves by pomegranate seed hydroalcoholic extract (Persian)]. HealthMED, 7, 348-358.
25. Sarkaki, A. R., Khaksari Haddad, M., Soltani, Z., Shahrokhi, N., & Mahmoodi, M. (2013). [Time- and dose-dependent neuroprotective effects of sex steroid hormones on inflammatory cytokines after a traumatic brain injury(Persian)]. J Neurotrauma, 30(1), 47-54. doi: 10.1089/neu.2010.1686
26. Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000). CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39(5), 777-787.
27. Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P., Cargnin-Ferreira, E., Da Cunha, C., & Takahashi, R. N. (2008). Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 156(4), 830-840. doi: 10.1016/j.neuroscience.2008.08.035
28. Tansey, M. G., & Goldberg, M. S. (2010). Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis, 37(3), 510-518. doi: 10.1016/j.nbd.2009.11.004
29. Uzar, E., Fi{dotless}rat, U., Altun, Y., Alp, H., Evliyaoglu, O., & Cevik, M. U. (2012). Ellagic acid attenuates oxidative stress on brain and sciatic nerve and improves histopathology of brain in streptozotocin-induced diabetic rats. Neurol Sci. doi: 10.1007/s10072-011-0775-1
30. Wada, L., & Ou, B. (2002). Antioxidant activity and phenolic content of Oregon caneberries. J Agric Food Chem, 50(12), 3495-3500.
31. Whitley, A. C., Stoner, G. D., Darby, M. V., & Walle, T. (2003). Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid--extensive binding to protein and DNA. Biochem Pharmacol, 66(6), 907-915.